Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
In 429 untreated patients with advanced EGFR-mutated NSCLC, aumolertinib prolonged median PFS versus gefitinib (19.3 vs 9.9 months; HR 0.46, 95% CI 0.36–0.60). Response rates and grade ≥3 adverse events were similar; rash and diarrhoea were less common.
RCTn = 429
Lu et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations